Severe Combined Immunodeficiency (SCID) Diagnosis Market to grow with a CAGR of 9.20% through 2030F

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market in the forecast period 2025-2030

According to TechSci Research report, “Severe Combined Immunodeficiency (SCID) Diagnosis Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2020-2030F”, Global Severe Combined Immunodeficiency (SCID) Diagnosis Market was valued at USD 182.60 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.20% through 2030.  This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

Newborn screening programs play a significant role in driving the demand for the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market. Newborn screening programs are designed to detect SCID in infants shortly after birth, often within the first few days of life. This early detection is crucial because it allows for timely intervention and treatment, reducing the risk of severe infections and complications associated with SCID. In many regions, newborn screening for SCID is becoming a standard practice and is included in universal newborn screening panels. This means that all newborns are screened, regardless of their risk factors or family history of SCID. Infants with SCID may appear healthy at birth and not show obvious symptoms. Newborn screening identifies affected infants before they develop symptoms, ensuring that they receive prompt medical attention. Newborn screening programs for SCID have been associated with a significant reduction in mortality rates among affected infants. Early diagnosis allows for timely initiation of treatment, such as hematopoietic stem cell transplantation (HSCT) or gene therapy, which can be lifesaving. Early intervention and treatment can lead to better outcomes for children with SCID, improving their overall quality of life. With appropriate care, many SCID patients can lead relatively normal lives. Detecting SCID early through newborn screening can lead to cost savings in the long run by preventing severe infections, hospitalizations, and the need for more extensive and expensive medical interventions.

Severe combined immunodeficiency (SCID) is a group of rare disorders caused by gene mutations that affect the development and functioning of immune cells responsible for fighting infections. Typically, the diagnosis of SCID involves a thorough medical history and a physical examination of the affected child. To confirm the diagnosis, additional blood tests, including a complete blood cell count, may be conducted. X-linked severe combined immunodeficiency (X-linked SCID) is a hereditary immune system disorder that overwhelmingly affects males. Due to a deficiency in essential immune cells, boys with X-linked SCID are susceptible to recurrent and prolonged infections caused by various bacteria, viruses, and fungi.

Interpreting genetic variants is a significant challenge in the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market. SCID is a genetically heterogeneous condition, meaning that there are multiple genes associated with different subtypes of SCID. Interpreting genetic variants becomes challenging because each subtype may have its own set of pathogenic mutations. Some genetic variants associated with SCID may be extremely rare or unique to specific families or populations. These rare variants can be challenging to interpret because there may be limited data available about their pathogenicity. Different genetic variants can lead to variations in the clinical presentation and severity of SCID. Some variants may result in milder forms of the condition, making it difficult to identify affected individuals based solely on symptoms. Novel or previously unidentified genetic variants continue to be discovered through genetic testing and research. Interpreting the pathogenicity of these new variants requires careful assessment and may involve functional studies to confirm their significance. In genetic testing, variants that do not have a known or well-established pathogenic role may be classified as "Variants of Uncertain Significance" (VUS). Interpreting VUS is challenging because their clinical significance is unclear, and they may or may not be related to SCID.

Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on "Global Severe Combined Immunodeficiency (SCID) Diagnosis Market.”

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market is segmented based on disease type, test type, end-user, and by region.

Based on end user, In 2024, the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market largest share was held by Hospital segment in the forecast period and is predicted to continue expanding over the coming years.  Hospitals typically have a team of specialized medical professionals, including immunologists, geneticists, and paediatricians, who are well-equipped to diagnose and manage rare conditions like SCID. This expertise is essential for accurate and timely diagnosis. Hospitals often have state-of-the-art diagnostic laboratories and equipment that can conduct a wide range of tests, including genetic sequencing and immunological assays, which are essential for SCID diagnosis. Many hospitals, particularly those with maternity and neonatal units, are actively involved in newborn screening programs. SCID is often included in these programs, enabling early detection and intervention. Some hospitals serve as regional or national referral centres for rare diseases like SCID. Patients with suspected or confirmed SCID are often referred to these specialized hospitals for diagnosis and treatment. Hospitals may collaborate with research institutions and universities to stay at the forefront of diagnostic developments and research on SCID. This collaborative effort can enhance diagnostic capabilities..

Based on region, Asia-pacific region to witness fastest growth in the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market. Many countries in the Asia-Pacific region have been investing in the expansion and modernization of their healthcare infrastructure. This includes improving medical facilities, diagnostic laboratories, and access to specialized healthcare services. Awareness about rare diseases like SCID is on the rise in the Asia-Pacific region due to efforts by healthcare organizations, patient advocacy groups, and educational campaigns. Increased awareness can lead to more infants being tested for SCID, contributing to the growth of the diagnosis market. Some countries in Asia-Pacific have initiated or expanded newborn screening programs to include SCID. Newborn screening allows for early detection and intervention, driving the demand for diagnostic tests. The Asia-Pacific region is home to a significant portion of the global population. The sheer number of births in this region contributes to a larger pool of potential SCID cases, which can drive the demand for diagnostic testing.

Some of the major companies operating in the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market include:

·         ARCHIMED SAS

·         PerkinElmer LAS Inc

·         Health Research, Inc

·         Winfertility Inc.

·         Portea Medical

·         LaCAR MDX Technologies

·         Labsystems Diagnostics Oy

·         Devyser Diagnostics

·         Revcovi

·         Leadiant Biosciences Inc.

Download Free Sample Report

Customers can also request 10% free customization on this report.

“Certain areas, particularly in North America, are projected to exert significant demand for Severe Combined Immunodeficiency (SCID) Diagnosis. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market in the forecast period", said Mr. Karan Chechi, Research Director of TechSci Research, a research-based Global management consulting firm.

"Severe Combined Immunodeficiency (SCID) Diagnosis Market – Global Industry Size, Share, Trends Segmented by Disease Type (X-linked SCID, ADA-SCID, others), By Test Type (TREC, Complete blood count (CBC), Genetic Test, Biochemical Test, others), By End User (Hospitals, Diagnostic and Research Laboratories, Others), By Region & Competition, 2020-2030F" has evaluated the future growth potential of Global Severe Combined Immunodeficiency (SCID) Diagnosis Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com